


26. A compound of structural formula I:



or a pharmaceutically acceptable salt thereof, wherein:

V and W are both N, or V and W are both CH;

Z is selected from CH and N, provided that when V and W are CH, then Z is not N;

R¹ is H, C₁₋₃ alkyl, C₁₋₃ alkoxy, F, or Cl;

R² is S(O)_n R⁶, COR⁶ or CHO, wherein:

n is 0, 1 or 2, and

R⁶ is N(R³)₂ or C₁₋₃ alkyl;

R³ is independently H or C₁₋₃ alkyl;

Ar is aryl or heteroaryl;

R⁴ and R⁵ are independently selected from:

(1) hydrogen,

(2) aryl, either unsubstituted or substituted with

(a) halo,

(b) C₁₋₃ alkoxy,


(c)-N(C₁₋₃ alkyl)₂,

(d) C₂₋₄ alkanoyl, or

(e) aryl,

- (3) nitro,
- (4) C₁₋₅ alkyl,
- (5) C₁₋₅ alkoxy,
- (6) hydroxy-C₁₋₃ alkyl,
- (7) carboxy,
- (8) halo,
- (9) C₁₋₅ alkylthio,
- (10) C₁₋₅ ethoxycarbonyl,
- (11) pyridylcarbonyl,
- (12) benzoyl,
- (13) phenyl-C₁₋₃ alkoxy,
- (14) pyridyl, either unsubstituted or substituted with
C₁₋₃ alkyl or C₁₋₃ alkoxy,
- (15) C₃₋₆ cycloalkyl,
- (16) oxazolyl,
- (17) thiazolyl,
- (18) triazolyl,
- (19) phenoxy, and
- (20) C₂₋₆ alkanoyl.


27. The compound of Claim 26 wherein Z, V and W are N.
28. The compound of Claim 27 wherein Ar is phenyl, of structural formula
I(a):



I(a)

or a pharmaceutically acceptable salt thereof.

31. The compound of Claim 30 wherein Ar is a 5- or 6-membered heteroaryl having, besides carbon atoms, 1 to 3 hetero atoms selected from N, O or S as atoms constituting the ring, or benzo- or pyrido- fused versions thereof of structural formula I(b):



I(b)


or a pharmaceutically acceptable salt thereof.

32. The compound of Claim 31 wherein R² is -SO₂(C₁₋₃ alkyl) or SO₂NH₂.

33. The compound of Claim 32 wherein R⁴ and R⁵ are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C₁₋₅ alkylpyridyl, benzhydryl, phenyl-C₁₋₃ alkoxy, NO₂, C₂₋₄ alkanoyl, halo, C₁₋₅ alkoxy, C₁₋₃ alkoxycarbonyl, C₁₋₅ alkylthio, triazolyl, carboxy, hydrogen, C₁₋₅ alkyl, pyridylcarboxy, and C₁₋₃ alkoxyphenyl.

34. The compound of Claim 26 wherein Z is CH and both V and W are N.

35. The compound of Claim 34 wherein Ar is phenyl, of structural formula I(a):




I(a)

or a pharmaceutically acceptable salt thereof.

36. The compound of Claim 35 wherein R² is -SO₂(C₁₋₃ alkyl) or SO₂NH₂.

37. The compound of Claim 36 wherein R⁴ and R⁵ are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C₁₋₅ alkylpyridyl, benzhydryl, phenyl-C₁₋₃ alkoxy, NO₂, C₂₋₄ alkanoyl, halo, C₁₋₅ alkoxy, C₁₋₃ alkoxycarbonyl, C₁₋₅ alkylthio, triazolyl, carboxy, hydrogen, C₁₋₅ alkyl, pyridylcarboxy, and C₁₋₃ alkoxyphenyl.

38. The compound of Claim 37 wherein Ar is a 5- or 6-membered heteroaryl having, besides carbon atoms, 1 to 3 hetero atoms selected from N, O or S as atoms constituting the ring, or benzo- or pyrido- fused versions thereof of structural formula I(b):



I(b)


or a pharmaceutically acceptable salt thereof.

39. The compound of Claim 38 wherein R² is -SO₂(C₁₋₃ alkyl) or SO₂NH₂.

40. The compound of Claim 39 wherein R⁴ and R⁵ are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C₁₋₅ alkylpyridyl, benzhydryl, phenyl-C₁₋₃ alkoxy, NO₂, C₂₋₄ alkanoyl, halo, C₁₋₅ alkoxy, C₁₋₃ alkoxy carbonyl, C₁₋₅ alkylthio, triazolyl, carboxy, hydrogen, C₁₋₅ alkyl, pyridylcarboxy, and C₁₋₃ alkoxyphenyl.

41. The compound of Claim 26 wherein Z, V and W are CH.

42. The compound of Claim 41 wherein Ar is phenyl, of structural formula I(a):




I(a)

or a pharmaceutically acceptable salt thereof.

43. The compound of Claim 42 wherein R² is -SO₂(C₁₋₃ alkyl) or SO₂NH₂.

44. The compound of Claim 43 wherein R⁴ and R⁵ are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C₁₋₅ alkylpyridyl, benzhydryl, phenyl-C₁₋₃ alkoxy, NO₂, C₂₋₄ alkanoyl, halo, C₁₋₅ alkoxy, C₁₋₃ alkoxycarbonyl, C₁₋₅ alkylthio, triazolyl, carboxy, hydrogen, C₁₋₅ alkyl, pyridylcarboxy, and C₁₋₃ alkoxyphenyl.

45. The compound of Claim 44 wherein Ar is a 5- or 6-membered heteroaryl having, besides carbon atoms, 1 to 3 hetero atoms selected from N, O or S as atoms constituting the ring, or benzo- or pyrido- fused versions thereof of structural formula I(b):




I(b)

or a pharmaceutically acceptable salt thereof.

46. The compound of Claim 45 wherein R^2 is $-SO_2(C_{1-3} \text{ alkyl})$ or SO_2NH_2 .

47. The compound of Claim 46 wherein R^4 and R^5 are independently selected from: phenyl, pyridyl, benzoyl, halophenyl, phenoxy, C_{1-5} alkylpyridyl, benzhydryl, phenyl- C_{1-3} alkoxy, NO_2 , C_{2-4} alkanoyl, halo, C_{1-5} alkoxy, C_{1-3} alkoxy carbonyl, C_{1-5} alkylthio, triazolyl, carboxy, hydrogen, C_{1-5} alkyl, pyridylcarboxy, and C_{1-3} alkoxyphenyl.





48. The compound of Claim 26 wherein R^2 is $-COR^6$ of structural formula I(d):



I(d)

or a pharmaceutically acceptable salt thereof.

49. The compound of Claim 48 or a pharmaceutically acceptable salt thereof selected from those depicted in the following Table:

<u>R⁶</u>	<u></u>
-CH ₃	
-CH ₃	
-CH ₃	

50. A method of treating Y5 receptor mediated disease selected from the group consisting of obesity, anorexia nervosa, bulimia nervosa, diabetes, hypertension, hyperlipemia, hypercholesterolemia, congestive heart failure, renal dysfunction, sexual/reproductive disorders, depression, anxiety, epileptic seizure, memory loss, migraine, cerebral hemorrhage, nasal congestion, gastrointestinal disorders, and arthritis, which comprises administering to a patient in need of such treatment a non-toxic therapeutically effective amount of a compound of Claim 26 that antagonizes the Y5 receptor.

51. The method of Claim 50 wherein the Y5 mediated disease is obesity.

52. A pharmaceutical composition which comprises a pharmaceutically acceptable carrier and an effective amount of a compound of claim 26.